Tags

Type your tag names separated by a space and hit enter

Grading Ductal Carcinoma In Situ (DCIS) of the Breast - What's Wrong with It?

Abstract

Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.

Authors+Show Affiliations

Department of Pathology, Bács-Kiskun County Teaching Hospital, Nyíri út 38, Kecskemét, H-6000, Hungary. cserni@freemail.hu. Department of Pathology, University of Szeged, Állomás u. 1, Szeged, H-6725, Hungary. cserni@freemail.hu.Department of Pathology, University of Szeged, Állomás u. 1, Szeged, H-6725, Hungary.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31776839

Citation

Cserni, Gábor, and Anita Sejben. "Grading Ductal Carcinoma in Situ (DCIS) of the Breast - What's Wrong With It?" Pathology Oncology Research : POR, 2019.
Cserni G, Sejben A. Grading Ductal Carcinoma In Situ (DCIS) of the Breast - What's Wrong with It? Pathol Oncol Res. 2019.
Cserni, G., & Sejben, A. (2019). Grading Ductal Carcinoma In Situ (DCIS) of the Breast - What's Wrong with It? Pathology Oncology Research : POR, doi:10.1007/s12253-019-00760-8.
Cserni G, Sejben A. Grading Ductal Carcinoma in Situ (DCIS) of the Breast - What's Wrong With It. Pathol Oncol Res. 2019 Nov 27; PubMed PMID: 31776839.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Grading Ductal Carcinoma In Situ (DCIS) of the Breast - What's Wrong with It? AU - Cserni,Gábor, AU - Sejben,Anita, Y1 - 2019/11/27/ PY - 2019/07/04/received PY - 2019/10/01/accepted PY - 2019/11/29/entrez PY - 2019/11/30/pubmed PY - 2019/11/30/medline KW - Breast cancer KW - Ductal carcinoma in situ KW - Grade JF - Pathology oncology research : POR JO - Pathol. Oncol. Res. N2 - Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection. SN - 1532-2807 UR - https://www.unboundmedicine.com/medline/citation/31776839/Grading_Ductal_Carcinoma_In_Situ_(DCIS)_of_the_Breast_-_What's_Wrong_with_It L2 - https://doi.org/10.1007/s12253-019-00760-8 DB - PRIME DP - Unbound Medicine ER -